Merger and Acquisition Trends in Pharma, Q4 2025
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report analyzes the merger and acquisition (M&A) activity in Q4 2025 in the Pharma sector.
Scope
This report provides an overview of M&A activity globally in Q4 2025 in the Pharma sector involving biopharmaceutical drug companies.
It identifies key trends, and the most notable deals announced in Q4 2025 in the Pharma sector.
Key Highlights
The global pharma sector in Q4 2025 saw a surge in deal value, with $80.2 billion worth of deals, representing an increase of 59.3% compared to Q3 2025. However, deal volume, declined by 12% to 103 M&A deals in Q4 2025. Oncology emerged as the leading therapeutic area recording 46 deals.
Reasons to Buy
Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Avidity Biosciences
Merck
Cidara Therapeutics
Novo Nordisk
Akero Therapeutics
BioMarin Pharmaceutical
Amicus Therapeutics
Johnson & Johnson
Halda Therapeutics
Alkermes
Avadel Pharmaceuticals
Sanofi
Dynavax Technologies
Ipsen
ImCheck Therapeutics
Bristol-Myers Squibb
Orbital Therapeutics
Swedish Orphan Biovitrum
Arthrosi Therapeutics
Abbott Laboratories
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports